1. Home
  2. ENTA vs CXDO Comparison

ENTA vs CXDO Comparison

Compare ENTA & CXDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTA
  • CXDO
  • Stock Information
  • Founded
  • ENTA 1995
  • CXDO 1995
  • Country
  • ENTA United States
  • CXDO United States
  • Employees
  • ENTA N/A
  • CXDO N/A
  • Industry
  • ENTA Biotechnology: Pharmaceutical Preparations
  • CXDO Telecommunications Equipment
  • Sector
  • ENTA Health Care
  • CXDO Telecommunications
  • Exchange
  • ENTA Nasdaq
  • CXDO Nasdaq
  • Market Cap
  • ENTA 160.3M
  • CXDO 152.4M
  • IPO Year
  • ENTA 2013
  • CXDO 1998
  • Fundamental
  • Price
  • ENTA $7.89
  • CXDO $6.43
  • Analyst Decision
  • ENTA Buy
  • CXDO Strong Buy
  • Analyst Count
  • ENTA 4
  • CXDO 3
  • Target Price
  • ENTA $18.00
  • CXDO $8.50
  • AVG Volume (30 Days)
  • ENTA 181.3K
  • CXDO 266.2K
  • Earning Date
  • ENTA 08-04-2025
  • CXDO 08-05-2025
  • Dividend Yield
  • ENTA N/A
  • CXDO N/A
  • EPS Growth
  • ENTA N/A
  • CXDO 51.44
  • EPS
  • ENTA N/A
  • CXDO 0.09
  • Revenue
  • ENTA $64,462,999.00
  • CXDO $62,609,000.00
  • Revenue This Year
  • ENTA N/A
  • CXDO $12.98
  • Revenue Next Year
  • ENTA $0.48
  • CXDO $10.91
  • P/E Ratio
  • ENTA N/A
  • CXDO $72.41
  • Revenue Growth
  • ENTA N/A
  • CXDO 13.85
  • 52 Week Low
  • ENTA $4.09
  • CXDO $3.01
  • 52 Week High
  • ENTA $17.24
  • CXDO $7.34
  • Technical
  • Relative Strength Index (RSI)
  • ENTA 67.33
  • CXDO 70.77
  • Support Level
  • ENTA $6.95
  • CXDO $5.67
  • Resistance Level
  • ENTA $8.23
  • CXDO $6.57
  • Average True Range (ATR)
  • ENTA 0.40
  • CXDO 0.27
  • MACD
  • ENTA 0.00
  • CXDO 0.10
  • Stochastic Oscillator
  • ENTA 75.11
  • CXDO 90.59

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

About CXDO Crexendo Inc.

Crexendo Inc is a provider of cloud communications, UCaaS, call centers, collaboration services, and other cloud business services. The company operates through two segments: Cloud telecommunications and Software Solutions. Its cloud telecommunications segment offers hardware, software, and unified communication solutions for businesses using IP or cloud technology over any high-speed Internet connection. The Software Solutions segment is involved in revenue generation from software licenses, software maintenance support, and professional services. It generates subscription and maintenance support revenue from customer support and other supportive services. The company offers warranties on its products. It derives a majority of its revenue from the Cloud telecommunications segment.

Share on Social Networks: